Abstract
The influence of posttransplant lymphoproliferative disorder (PTLD) on long-term survival in children after heart transplantation (HTx) is not well studied. The United Network for Organ Sharing database was queried from 1987 to 2013 for data on PTLD in relation to induction immunosuppression and recipient Epstein–Barr virus status in children (<18 years of age) who underwent HTx. Of 6818 first-time pediatric heart transplants, 5169 had follow-up data on posttransplant malignancy, with 360 being diagnosed with PTLD. Univariate Cox analysis identified diminished survival after PTLD onset using a time-varying measure of PTLD (HR 2.208; 95 % CI 1.812, 2.689; p < 0.001), although Kaplan–Meier survival functions found no difference in survival between the group ever diagnosed with PTLD and the non-PTLD reference group (log-rank test: χ 21 = 0.02; p = 0.928). A multivariate Cox model found a greater mortality hazard associated with the development of PTLD after adjusting for recipient EBV seronegativity and other covariates (HR 3.024; 95 % CI 1.902, 4.808; p < 0.001). Induction immunosuppression at time of HTx did not significantly influence posttransplant mortality. The development of PTLD adversely influenced long-term survival in children after HTx after adjusting for confounding variables.
Similar content being viewed by others
References
Aris RM, Maia DM, Neuringer IP, Gott K, Kiley S, Gertis K, Handy J (1996) Post-transplantation lymphoproliferative disorder in the Epstein–Barr virus-naïve lung transplant recipient. Am J Respir Crit Care Med 154(6 Pt 1):1712–1717
Chadburn A, Suciu-Foca N, Cesarman E, Reed E, Michler RE, Knowles DM (1995) Post-transplantation lymphoproliferative disorders arising in solid organ transplant recipients are usually of recipient origin. Am J Pathol 147(6):1862–1870
Chinnock R, Webber SA, Dipchand AI, Brown RN, George JF (2012) Pediatric heart transplant study. A 16-year multi-institutional study of the role of age and EBV status on PTLD incidence among pediatric heart transplant recipients. Am J Transplant 12(11):3061–3068
Crespo-Leiro MG, Alonso-Pulpón L, de Vázquez Prada JA, Almenar L, Arizón JM, Brossa V, Delgado JF, Fernandez-Yañez J, Manito N, Rábago G, Lage E, Roig E, Diaz-Molina B, Pascual D, Muñiz J (2008) Malignancy after heart transplantation: incidence, prognosis and risk factors. Am J Transplant 8(5):1031–1039
Dharnidharka VR, Araya CE (2009) Post-transplant lymphoproliferative disease. Pediatr Nephrol 24(4):731–736
Dharnidharka VR, Lamb KE, Gregg JA, Meier-Kriesche HU (2012) Associations between EBV serostatus and organ transplant type in PTLD risk: an analysis of the SRTR National Registry Data in the United States. Am J Transplant 12(4):976–983
Dipchand AI, Edwards LB, Kucheryavaya AY, Benden C, Dobbels F, Levvey BJ, Lund LH, Meiser B, Yusen RD, Stehlik J (2014) International Society of Heart and Lung Transplantation. The registry of the International Society for Heart and Lung Transplantation: seventeenth official pediatric heart transplantation report-2014; focus theme: retransplantation. J Heart Lung Transplant 33(10):985–995
Haque T, Thomas JA, Falk KI, Parratt R, Hunt BJ, Yacoub M, Crawford DH (1996) Transmission of donor Epstein–Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients. J Gen Virol 77(Pt 6):1169–1172
Huebler M, Schubert S, Lehmkuhl HB, Weng Y, Miera O, Alexi-Meskishvili V, Berger F, Hetzer R (2011) Pediatric heart transplantation: 23-year single-center experience. Eur J Cardiothorac Surg 39(5):e83–e89
Lund LH, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI, Dobbels F, Goldfarb SB, Levvey BJ, Meiser B, Yusen RD, Stehlik J (2014) International Society of Heart and Lung Transplantation. The registry of the International Society for Heart and Lung Transplantation: thirty-first official adult heart transplant report-2014; focus theme: retransplantation. J Heart Lung Transplant 33(10):996–1008
Nourse JP, Jones K, Gandhi MK (2011) Epstein–Barr virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy. Am J Transplant 11(5):888–895
Ohta H, Fukushima N, Ozono K (2009) Pediatric post-transplant lymphoproliferative disorder after cardiac transplantation. Int J Hematol 90(2):127–136
Schubert S, Abdul-Khaliq H, Lehmkuhl HB, Yegitbasi M, Reinke P, Kebelmann-Betzig C, Hauptmann K, Gross-Wieltsch U, Hetzer R, Berger F (2009) Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients. Pediatr Transplant 13(1):54–62
United Network for Organ Sharing/Organ Procurement and Transplantation Network Standard Transplant Analysis and Research Database. http://optn.transplant.hrsa.gov/data/about/OPTNDatabase.asp. Accessed 6 Sep 2013
Végso G, Hajdu M, Sebestyén A (2011) Lymphoproliferative disorders after solid organ transplantation–classification, incidence, risk factors, early detection and treatment options. Pathol Oncol Res 17(3):443–454
Webber SA, Naftel DC, Fricker FJ, Olesnevich P, Blume ED, Addonizio L, Kirklin JK, Canter CE (2006) Pediatric heart transplant study. Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study. Lancet 367(9506):233–239
Acknowledgments
The authors would like to acknowledge Dmitry Tumin for his statistical expertise in the data analysis.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No funding supported this work.
Conflict of interest
The authors have no relevant disclosures or conflict of interest to report.
Rights and permissions
About this article
Cite this article
Hayes, D., Breuer, C.K., Horwitz, E.M. et al. Influence of Posttransplant Lymphoproliferative Disorder on Survival in Children After Heart Transplantation. Pediatr Cardiol 36, 1748–1753 (2015). https://doi.org/10.1007/s00246-015-1229-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00246-015-1229-y